Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252)

Detalles Bibliográficos
Autores principales: Gonzalez-Rodriguez, Elena, Aubry-Rozier, Bérengère, Stoll, Delphine, Zaman, Khalil, Lamy, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385537/
https://www.ncbi.nlm.nih.gov/pubmed/32742916
http://dx.doi.org/10.1016/j.jbo.2020.100294
_version_ 1783563806103830528
author Gonzalez-Rodriguez, Elena
Aubry-Rozier, Bérengère
Stoll, Delphine
Zaman, Khalil
Lamy, Olivier
author_facet Gonzalez-Rodriguez, Elena
Aubry-Rozier, Bérengère
Stoll, Delphine
Zaman, Khalil
Lamy, Olivier
author_sort Gonzalez-Rodriguez, Elena
collection PubMed
description
format Online
Article
Text
id pubmed-7385537
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73855372020-07-30 Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252) Gonzalez-Rodriguez, Elena Aubry-Rozier, Bérengère Stoll, Delphine Zaman, Khalil Lamy, Olivier J Bone Oncol Commentary Elsevier 2020-04-28 /pmc/articles/PMC7385537/ /pubmed/32742916 http://dx.doi.org/10.1016/j.jbo.2020.100294 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Commentary
Gonzalez-Rodriguez, Elena
Aubry-Rozier, Bérengère
Stoll, Delphine
Zaman, Khalil
Lamy, Olivier
Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252)
title Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252)
title_full Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252)
title_fullStr Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252)
title_full_unstemmed Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252)
title_short Commentary to “Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials” (Galvano et al. J Bone Oncol 2019; 18:100252)
title_sort commentary to “denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? a systematic review and a meta-analysis of randomized trials” (galvano et al. j bone oncol 2019; 18:100252)
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385537/
https://www.ncbi.nlm.nih.gov/pubmed/32742916
http://dx.doi.org/10.1016/j.jbo.2020.100294
work_keys_str_mv AT gonzalezrodriguezelena commentarytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252
AT aubryrozierberengere commentarytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252
AT stolldelphine commentarytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252
AT zamankhalil commentarytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252
AT lamyolivier commentarytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252

Ejemplares similares